BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 18, 2019
View Archived Issues
Amgen's monoclonal antibody targeting ASGPR 1 well tolerated in phase I study
Read More
Workaround may be mutation agnostic treatment for cystic fibrosis
Read More
Equillium initiates phase I/II study of EQ-001
Read More
Japanese researchers present phase I data for GEN-0101 in CRPC
Read More
ZV-0508 as a promising new ADC candidate for the treatment of 5T4-positive cancers
Read More
Plasma protein profiling identifies new protein biomarkers associated with NAFLD
Read More
New method greenlights Myc targeting
Read More
TPH1 inhibitors patented by Gwangju Institute of Science and Technology and collaborators
Read More
Overcoming resistance in KRAS-mutant tumors
Read More
Merck & Co. discovers proteasome subunit beta type-8 inhibitors
Read More
Helmholtz-Zentrum fuer Infektionsforschung presents E. coli DNA gyrase inhibitors
Read More
The University of Rochester identifies new angiogenesis inhibitors
Read More
Gilead identifies new indoleamine 2,3-dioxygenase 1 inhibitors
Read More
Praluent approved in Europe to reduce CV risk in adults with established atherosclerotic CV disease
Read More
Stroke candidate pyragrel safe and well tolerated in phase I study
Read More
PK/PD evaluation of a single dose of nilotinib in Parkinson's disease patients
Read More
First-in-human data presented for KL-1333
Read More
New phase I study evaluates CyPep-1 for HPV-induced warts
Read More
Aerie begins phase II study of AR-1105 for macular edema due to RVO
Read More
New phase II trial assesses TLC-590 for postsurgical pain management following bunionectomy
Read More
ReNeuron advances phase I/II retinitis pigmentosa trial of hRPC cell therapy candidate
Read More
Allergy Therapeutics' phase III trial of adjuvanted birch allergoid product misses primary endpoint
Read More
Phase IIb study of lebrikizumab in moderate to severe atopic dermatitis meets primary endpoint
Read More
resTORbio announces plans for phase III program with RTB-101 for respiratory tract infections
Read More
European Commission approves MabThera for pemphigus vulgaris
Read More
Lexicon initiates phase IIa study of telotristat ethyl in biliary tract cancer
Read More